Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case series

Submitted: June 21, 2023
Accepted: September 27, 2023
Published: October 3, 2023
Abstract Views: 485
PDF_early view: 177
Video 1: 0
Video 2: 0
Video 3: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Cavitating lung tumors occur in approximately 10-15% of the patients, are more commonly associated with squamous histology, and are typically located in the lung parenchyma. Herein we describe an exceedingly rare series of 5 patients, 4 of whom treatment-naïve, whose tumor caused the disruption of the normal airway anatomy at the level of lobar or segmental bronchi, leading to the formation of an endoscopically-visible cavity which ended up in the lung parenchyma or even into the pleural space. Sex (3 males, 2 females), smoking habit (2 never smokers, 2 former smokers, 1 current smoker), and histology (3 adenocarcinoma, 2 squamous cell carcinoma) were heterogeneous, but the 4 patients treatment-naïve presented with metastatic disease, poor ECOG performance status, similar clinical complaints of long duration, and lack of actionable mutations. The only patient who exhibited a meaningful response to treatment had the lowest symptoms’ duration, the smallest size of the cavitated mass, and the best performance status at the time of diagnosis. This series provides the first comprehensive description of a rare presentation of lung cancer characterized by similar clinical complaints, delayed diagnosis and poor prognosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008;3:351-7 DOI: https://doi.org/10.1097/JTO.0b013e318168c7e9
Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404-10. DOI: https://doi.org/10.1200/JCO.2008.16.2545
Calvetti L, Aprile G. influence and mechanisms of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat? Transl Lung Canc Res 2019; 8: 319-22. DOI: https://doi.org/10.21037/tlcr.2019.08.19
Wang R, Li K, Pi J, Zhu M. Cavitation and fatal hemopthysis after immunotherapy for advanced lung adenocarcinoma: a case report. Thorac Cancer 2020;11:2727-30. DOI: https://doi.org/10.1111/1759-7714.13578
Zarogoulidis P, Athanasiou E, Tsiouda T, et al. Immunotherapy “shock”: a case series of PDL1 100% and pembrolizumab first-line treatment. Resp Med Case Rep 2017;22:197-202. DOI: https://doi.org/10.1016/j.rmcr.2017.08.017
Phernambucq E, Hartemink K, Smit E, et al. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. J Thorac Oncol 2012;7:1271-5. DOI: https://doi.org/10.1097/JTO.0b013e3182582912
Sandler AB, Schiller JH, Gray R3, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12. DOI: https://doi.org/10.1200/JCO.2008.16.2412
Tokito T, Shukuya T, Akamatsu H, et al. Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. Resp Invest 2014;52:184-9. DOI: https://doi.org/10.1016/j.resinv.2013.12.004
Razazi K, Parrot A, Khalil A, et al. Severe haemoptysis in patients with non-small-cell lung cancer. Eur Resp J 2015;45:756-64. DOI: https://doi.org/10.1183/09031936.00010114
Ito M, Niho S, Nihei K, Yoh K, Ohmatsu H, Ohe Y. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 2012;12:27. DOI: https://doi.org/10.1186/1471-2407-12-27
Nguyen NC, Abhisheck K, Nyon S, et al. Are there radiographic, metabolic, and prognostic differences between cavitary and non-cavitary nonsmall cell lung carcinoma? A retrospective fluorodeoxyglucose positron emission tomography/computed tomography study. Ann Thorac Med 2016;11:49-56. DOI: https://doi.org/10.4103/1817-1737.165296
Pentheroudakis G, Kostadima L, Fountzilas G, et al. Cavitating squamous cell lung carcinoma – distinct entity or not? Analysis of radiologic, histologic and clinical features. Lung Cancer 2004;45:349-55. DOI: https://doi.org/10.1016/j.lungcan.2004.02.013
Liu Z, Feng H, Zhang Z, et al. Clinicopathological characteristics of solitary cavitary lung cancer: a case-control study. J Thorac Dis 2020;12:3148-56. DOI: https://doi.org/10.21037/jtd-20-426
Corradetti MN, Haas AR, Rengan RR. Central airway necrosis after stereotactic body-radiation therapy. N Engl J Med 2012;366:2327-29. DOI: https://doi.org/10.1056/NEJMc1203770
Alraiyes AH, Alraies MC, Abbas A. Radiation-associated airway necrosis. Ochsner J 2013;13:273-5.
Kim IA, Koh HK, Kim SJ, et al. Malignant tracheal necrosis and fistula formation following palliative chemoradiotherapy: a case report. J Thorac Dis 2017;9:E402-7. DOI: https://doi.org/10.21037/jtd.2017.04.19
Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020;21:1023-34. DOI: https://doi.org/10.1016/S1470-2045(20)30388-0
Leong TL. Delayed access to lung cancer screening and treatment during the COVID-19 pandemic: are we headed for a lung cancer pandemic? Respirology 2021;26:145-6. DOI: https://doi.org/10.1111/resp.13996
Trisolini R, Magnini D, Livi V, et al. Pattern of cancer patient referral and organizational model of an interventional pulmonology programme during the Covid-19 pandemic. ERJ Open Res 2021;7:00152-2021. DOI: https://doi.org/10.1183/23120541.00152-2021

How to Cite

Magnini, Daniele, Emilio Bria, Alessandra Cancellieri, Vanina Livi, Fausto Leoncini, Marco Ferrari, Teresa Bruni, Daniela Paioli, and Rocco Trisolini. 2023. “Bronchoscopically-Visible Massive Central Airway Cancer Cavitation Is Associated With Metastatic Disease, Lack of Actionable Mutations and Poor Prognosis: A Case Series”. Monaldi Archives for Chest Disease, October. https://doi.org/10.4081/monaldi.2023.2670.